Schizophrenia News

Patients with severe mental illness are less likely to receive revascularization therapies for treatment of STEMI, according to a recent study published in the American Journal of Cardiology.

Recent findings indicated significant overlap between genetic factors associated with schizophrenia risk and genetic factors associated with age at first birth.

ABT-126, a selective 7 nicotinic receptor partial agonist, significantly improved cognitive outcomes in individuals with schizophrenia who were nonsmokers, according to recent findings.

Emerging research on the development, prodromal characteristics and long-term course of schizophrenia may contribute to developing new treatments and preventive measures for schizophrenia, according to an issue of Harvard Review of Psychiatry.

Allergan recently announced that Vraylar, a once-daily oral atypical antipsychotic, is now available by prescription in pharmacies throughout the United States.

Refugees had an increased risk for psychosis and non-affective psychotic disorders compared with non-refugee migrants and native-born Swedish individuals.

Recent findings provide evidence that neurodevelopmental factors cause changes in the cellular composition of white matter circuits essential to high cognitive function.

LAS VEGAS — Mandy Fauble, PhD, of Safe Harbor Behavioral Health, UPMC Hamot, Erie, Pennsylvania, discusses how the Early Onset Schizophrenia Community of Practice is revolutionizing treatment for psychosis.

Progressive brain loss in schizophrenia reflects accelerated aging of the brain and potentially individual variation and medication use, according to recent findings.

Recent findings suggest that cannabis use in individuals with first-episode psychosis may be associated with antipsychotic treatment failure and lead to poorer clinical outcomes.